|February 5, 2014|
|08:34 EDT||SRPT||Sarepta announces Eteplirsen demonstrates stability through Phase IIb study|
Sarepta Therapeutics announced new pulmonary function data through Week 120 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy. Results through more than two years of treatment showed stable pulmonary function in the Intent-to-Treat study population. These data are consistent with previously reported 120-week clinical data showing a general stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test. Results through Week 120 for other exploratory efficacy endpoints, including timed function tests and the North Star Ambulatory Assessment have shown declines compared to baseline. These endpoints are less well characterized in DMD patients than the 6MWT and pulmonary function tests and have more inter- and intra-patient variability, although they may be predictors of decline at various stages of this disease. All patients evaluable on measures of ambulation are still able to perform these tests with the exception of one patient who is no longer able to perform the Gowers’ maneuver. Eteplirsen was well tolerated through week 120 and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events. In addition, there were no hospitalizations or discontinuations.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
|July 25, 2014|
|09:57 EDT||SRPT||Sarepta CSO had 'serious disagreements' with CEO, WSJ reports|
Sarepta's recently terminated Chief Scientific Officer Arthur Krieg said he had "serious disagreements" with CEO Chris Garabedian, Wall Street Journal reported last night, citing comments from a phone interview. Krieg's termination follows other management departures and "interrupts" the process" of preparing eteplirsen paperwork for the FDA, the Journal added, citing a person familiar with the matter. Recall that The Street's Adam Feuerstein reported yesterday that Krieg had no role in the clinical development of eteplirsen. Reference Link
|July 24, 2014|
|09:37 EDT||SRPT||Sarepta fired CSO not involved in eteplirsen, The Street reports|
Sarepta's just fired Chief Scientific Officer Art Krieg had no role in the clinical development of eteplirsen, The Street's Adam Feuerstein reports, citing two sources familiar with the situation. Krieg's exit relates to Sarepta being behind schedule in bringing new drugs into the clinic, Feuerstein adds. Reference Link
|09:16 EDT||SRPT||On The Fly: Pre-market Movers|
Subscribe for More Information
|06:52 EDT||SRPT||Sarepta terminates Chief Scientific Officer Arthur Krieg|
Sarepta disclosed that on July 22, Arthur Krieg, M.D., the company's Chief Scientific Officer, was terminated from his position. No other information was provided in the regulatory filing disclosing the news.
|July 22, 2014|
|10:00 EDT||SRPT||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: Abengoa Yield (ABY) initiated with an Equal Weight at Morgan Stanley... Actinium Pharmaceuticals (ATNM) initiated with a Buy at Canaccord... Axys Technologies (AXYS) initiated with a Buy at Dougherty... Chambers Street Properties (CSG) initiated with a Neutral at SunTrust... Enphase Energy (ENPH) initiated with a Buy at Dougherty... Minerals Technologies (MTX) initiated with an Outperform at Wedbush... NextEra Energy Partners (NEP) initiated with a Buy at BofA/Merrill... PTC Therapeutics (PTCT) initiated with a Buy at BofA/Merrill... QIWI (QIWI) initiated with a Positive at Susquehanna... Quality Systems (QSII) initiated with a Buy at Topeka... Sarepta (SRPT) initiated with a Neutral at BofA/Merrill... Trinseo S.A. (TSE) initiated with a Buy at BofA/Merrill... Washington Prime Group (WPG) initiated with a Neutral at SunTrust... Zhaopin (ZPIN) initiated with a Buy at UBS.
|07:11 EDT||SRPT||Sarepta initiated with a Neutral at BofA/Merrill|
Subscribe for More Information